Abstract
Cancer patients receiving programmed death 1 (PD-1) immune checkpoint blockade therapy are susceptible, due to immunosuppression, to a variety of infections including cytomegalovirus infection. We report an unusual case of histologically confirmed gastritis due to cytomegalovirus infection in a patient who had metastatic melanoma and received PD-1 blockade therapy with pembrolizumab. Pembrolizumab was discontinued and treatment with intravenous ganciclovir and oral vangaciclovir was initiated; the patient's symptoms improved significantly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
